Neoadjuvant Chemotherapy and Hormonal Therapy Followed by Radical Prostatectomy: Feasibility and Preliminary Results

Pettaway, Curtis A.; Pisters, Louis L.; Troncoso, Patricia; Slaton, Joel W.; Finn, Laury; Kamoi, Kazumi; Logothetis, Christopher J.

doi:10.1200/jco.2000.18.5.1050

Cited by 125 publications

(44 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the study by Cowen et al (24), prostate tumor growth in vivo was inhibited supraadditively when p53 null and p53 wild-type tumors were treated with INGN 201 and 5 Gy radiation. The biochemical disease-free survival of patients treated with INGN 201 and radical prostatectomy is similar to the biochemical disease-free survival of similar staged locally advanced patients treated with systemic chemotherapy followed by radical prostatectomy (33). It is conceivable that the biochemical results of patients treated with INGN 201 in a preoperative setting might improve if INGN 201 was used in combination with other proapoptotic stimuli such as hormonal therapy or systemic chemotherapy.…”

Section: Discussionmentioning

confidence: 56%

Evidence That Transfer of Functional p53 Protein Results in Increased Apoptosis in Prostate Cancer

Pisters¹,

Pettaway²,

Troncoso³

et al. 2004

Clinical Cancer Research

Self Cite

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 56%

Evidence That Transfer of Functional p53 Protein Results in Increased Apoptosis in Prostate Cancer

Pisters¹,

Pettaway²,

Troncoso³

et al. 2004

Clinical Cancer Research

Self Cite

View full text Add to dashboard Cite

“…9 Recently, neoadjuvant chemotherapy for men with high-risk localized PCa has been tested in several small clinical trials. 5,[10][11][12][13][14][15][16] For patients who received single-agent docetaxel, a substantial PSA decline (>50%) was observed in 50% to 100% of patients, but no pathologic complete response was reported. 5,11,15 Similar to the study by Febbo et al, we detected no pathologically complete responses in patients with high-risk, localized PCa who received docetaxel prior to undergoing RP.…”

Section: Discussionmentioning

confidence: 99%

Neoadjuvant docetaxel treatment for locally advanced prostate cancer

Magi‐Galluzzi

Zhou

Reuther

et al. 2007

Cancer

View full text Add to dashboard Cite

BACKGROUND. The objective of the current study was to determine the histologic and molecular changes that occurred in patients with high‐risk, localized prostate cancer (PCa) after neoadjuvant docetaxel chemotherapy. METHODS. Patients who had locally advanced PCa (serum preoperative [initial] prostate‐specific antigen [iPSA] level ≥15 ng/mL, or clinical ≥T2b disease, or biopsy Gleason score [GS] ≥8) and no evidence of metastatic disease received 6 doses of intravenous docetaxel (40 mg/m2) administered weekly for 6 weeks followed by radical prostatectomy (RP). The Wilcoxon signed‐rank test was used to compare pretreatment and posttreatment markers. RESULTS. Twenty‐eight patients completed chemotherapy and underwent RP at the Cleveland Clinic; none achieved a pathologic complete response. Pretreatment diagnostic prostate biopsies (PBx) were reviewed in all patients, and unstained sections of formalin‐fixed tissue were available from 11 patients. The median patient age was 62 years (range, 49–72 years), and the median iPSA was 6.8 ng/mL (range, 2.5–24 ng/mL). At a median follow‐up of 49.5 months (range, 23–72 months), 12 patients (43%) remained clinically and biochemically free of disease with no additional therapy, and 16 patients (57%) had biochemical failure. The pretreatment GS was 6 in 2 patients (7%), 7 in 10 patients (36%), 8 in 11 patients (39%) and 9 in 5 patients (18%). Two patients (7.1%) had organ‐confined disease, and 23 patients (82.1%) had extraprostatic extension. Four patients (14.3%) had positive lymph nodes, and 11 patients (39.3%) had seminal vesicle involvement. Immunohistochemical (IHC) staining for a panel of markers involved in various cellular functions (α‐methylacyl‐coenzyme A racemase [AMACR], β‐tubulin I, β‐tubulin III, cyclin D1, p27, p21, Ki‐67, p53, Bcl‐2, and an apoptosis detection kit [ApopTag]) was performed on a tissue microarray that contained the posttreatment (RP) tissue specimens and on the PBx specimens, if available. When the IHC staining patterns were compared between PBx and RP specimens using the Wilcoxon signed‐rank test, only p53 expression (P = .017) and Bcl‐2 expression (P = .014) were found to be increased significantly after neoadjuvant docetaxel treatment. However, after performing the Bonferroni adjustment, these differences were no longer significant (P > .005). Ki‐67, ApopTag, β‐tubulin I, and β‐tubulin III expression levels also were increased after treatment; however, the differences were not found to be statistically significant. The expression levels of AMACR, p27, p21, and cyclin D1 were comparable in pretreatment and posttreatment specimens. CONCLUSIONS. The current results indicated that, although it will require longer follow‐up studies and larger numbers of patients to ascertain the value of neoadjuvant treatment, the negative findings of the current study may explain the lack of clinical response in patients who received neoadjuvant docetaxel for PCa. Although the results were subject to interpretation limits based on the study size, the increa...

show abstract

“…13 Диагностика и лечение опухолей мочеполовой системы. Рак предстательной железы опухолевой химиотерапии при гормоночувствитель-ном РПЖ в качестве адъювантного воздействия [2][3][4][5], демонстрирующие противоречивые результаты.…”

Section: Introductionunclassified

Adjuvant chemotherapy after radical prostatectomy in patients with stage III–IV prostate cancer without distant metastases

Поляков¹

2018

Cancer Urology

View full text Add to dashboard Cite

Диагностика и лечение опухолей мочеполовой системы. Рак предстательной железыАдъювантная химиотерапия после радикальной простатэктомии у пациентов, страдающих раком предстательной железы III-IV стадии без отдаленных метастазов

show abstract

Neoadjuvant Chemotherapy and Hormonal Therapy Followed by Radical Prostatectomy: Feasibility and Preliminary Results

Cited by 125 publications

References 32 publications

Evidence That Transfer of Functional p53 Protein Results in Increased Apoptosis in Prostate Cancer

Evidence That Transfer of Functional p53 Protein Results in Increased Apoptosis in Prostate Cancer

Neoadjuvant docetaxel treatment for locally advanced prostate cancer

Adjuvant chemotherapy after radical prostatectomy in patients with stage III–IV prostate cancer without distant metastases

Contact Info

Product

Resources

About